One of the most comprehensive lipid metabolism assessments

Framingham, Massachusetts, October March 3, 2022 /PRNewswire/ — Boston Heart Diagnostics is pleased to announce the launch of LipoMap™.This group of 33 lipids, lipoproteins and Apolipoprotein Tested by high-resolution 600 MHz nuclear magnetic resonance (NMR), it is one of the most comprehensive assessments of lipid metabolism on the market. Undertreated lipid abnormalities lead to persistent arterial damage, a common cause of premature cardiovascular disease (CVD) and sudden death. LipoMap™ supports healthcare providers to reduce risk and improve patient outcomes by identifying hidden abnormalities.Despite continued efforts, cardiovascular disease remains the leading cause of death in the country U.S. and the whole world. This innovative tool from Boston Heart supports clinicians’ ongoing mission to reduce this disease.

(PRNewsfoto/Boston Heart Diagnostics)

(PRNewsfoto/Boston Heart Diagnostics)

LipoMap revealed multiple treatable and reversible lipid abnormalities that contribute to CVD.

LipoMap™ revealed a variety of treatable and reversible lipid abnormalities that contribute to CVD, including in patients receiving statins and in patients with normal low-density lipoprotein (LDL) cholesterol levels. Uncovering these characteristics could enable greater personalization of treatment, such as improved drug regimens and targeted lifestyle interventions. Subsequent LipoMap™ tests allow physicians and patients to measure improvements from enhanced therapy.

LipoMap™ is available from Boston Heart and can be ordered exclusively by healthcare professionals. Just 1 mL of blood is required as a test sample and results are reported via the secure portal within a week.The report targets 33 lipids, lipoproteins and Apolipoprotein test results. These include essential lipids, direct LDL-C, low density LDL-C, apoA-I, ApoA-II, ApoB, and particle concentrations for LDL, IDL, VLDL, HDL, and the six LDL particle subspecies. LipoMap™ also provides the concentrations of ApoB-100 and triglycerides in LDL, IDL, and VLDL particles​​, as well as related ratios, including ratios of free cholesterol to esterified cholesterol in HDL and LDL, which are increased with treatment.

Healthcare providers can access the LipoMap™ by contacting Boston Heart Diagnostics 877.425.1252 Or email

About Boston Cardiac Diagnostics

Boston Heart Diagnostics, a subsidiary of Eurofins Scientific (EUFI.PA), is committed to transforming the treatment of cardiovascular disease and related diseases by providing healthcare providers and their patients with novel personalized diagnostics and comprehensive customized lifestyle programs with transformative capabilities. Physicians and patients communicate about disease and ways to improve health.For more information on Boston Heart, visit



View original content and download multimedia: – 301639142.html

Source Boston Heart Diagnostics

Source link